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RESEARCH ARTICLE
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To determine whether SRD5A2 promoter methylation is associated with cancer progression
during androgen deprivation therapy (ADT) in CRPC.
Patients and methods
In a Local CRPC cohort, 42 prostatic specimens were collected from patients who were
diagnosed as CRPC and underwent transurethral resection of the prostate (TURP) at Mas-
sachusetts General Hospital (MGH). In a metastatic CRPC (Met CRPC) cohort, 12 meta-
static biopsies were collected from CRPC patients who would be treated with abiraterone
plus dutasteride (Clinical Trial NCT01393730). As controls, 36 benign prostatic specimens
were collected from patients undergoing prostate reduction surgery for symptoms of bladder
outlet obstruction secondary to benign prostatic hyperplasia (BPH). The methylation status
of cytosine-phosphate-guanine (CpG) site(s) at SRD5A2 promoter regions was tested.
Results
Compared with benign prostatic tissue, CRPC samples demonstrated higher SRD5A2
methylation in the whole promoter region (Local CRPC cohort: P < 0.001; Met CRPC cohort:
P <0.05). In Local CRPC cohort, a higher ratio of methylation was correlated with better OS
(R2 = 0.33, P = 0.013). Hypermethylation of specific regions (nucleotides -434 to -4 [CpG#
-39 to CpG# -2]) was associated with a better OS (11.3±5.8 vs 6.4±4.4 years, P = 0.001)
and PFS (8.4±5.4 vs 4.5±3.9 years, P = 0.003) with cutoff value of 37.9%. Multivariate
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analysis showed that SRD5A2 methylation was associated with OS independently (whole
promoter region: P = 0.035; specific region: P = 0.02).
Conclusion
Our study demonstrate that SRD5A2 methylation in promoter regions, specifically at CpG#
-39 to -2, is significantly associated with better survival for CRPC patients treated with ADT.
Recognition of epigenetic modifications of SRD5A2 may affect the choices and sequence of
available therapies for management of CRPC.
Introduction
Advanced castration resistant prostate cancer (CRPC) accounts for majority of 31,000 deaths
each year in the United States, and prognostic tools that determine patients’ overall survival (OS)
are lacking [1, 2]. Oral inhibitors targeting CYP-17 (by abiraterone) and the androgen receptor
(AR) (by enzalutamide, apalutamide, darolutamide) have increased survival in CRPC in phase III
studies [3–8]. However, resistance to AR-directed therapies remains a challenge, which indicates
a complexity in the progression from invasive cancer to castration-resistant disease. Persistent AR
signaling despite AR-axis inhibition is a critical mechanism of resistance in patients with meta-
static CRPC (Met CRPC) [9]. Thus, a better understanding of the drivers in resistance is needed
to develop therapeutic strategies that offer patients long-term clinical benefit.
Predictive biomarkers identifying CRPC patients who respond optimally to androgen dep-
rivation therapy (ADT) is of great clinical importance. One mechanism of CRPC development
is intratumoral biosynthesis of dihydrotestosterone (DHT) from adrenal precursors, which
requires three enzymatic steps. 5-α reduction catalyzed by steroid 5-α reductase (SRD5A) is
one of the three steps [10]. SRD5A has three isoforms, SRD5A1, SRD5A2 and SRD5A3. A
recent study demonstrated that the expression of SRD5A1 and SRD5A2 are inversely modu-
lated by AR activation, i.e., SRD5A1 transcription is activated but SRD5A2 is repressed, favor-
ing a transcriptional isoform switch that correlates with SRD5A expression patterns in human
tumors [11]. In metastatic prostate cancer (PCa) models, in vitro studies have shown that
SRD5A1 is upregulated in the Met CRPC setting and is directly regulated by androgens [11–
13]. In addition, patients carrying the more active GG genotype in SRD5A2 rs523349 exhibited
a higher risk of the progression and death, suggesting that high 5α-reductase activity due to
SRD5A2 rs523349 polymorphism may contribute to resistance to ADT in CRPC [14]. The
mechanism underlying this transcriptional regulatory switch is still unknown.
In benign prostatic tissue, expression of SRD5A2 protein is variable and negatively corre-
lated with methylation of the SRD5A2 promoter. Our recent studies show that 30% of adult
prostates without malignancy do not express the SRD5A2 gene or protein, and that somatic
suppression of SRD5A2 during adulthood is dependent on epigenetic changes associated with
methylation of the promoter region of the SRD5A2 gene [15–17]. In this study, we tested
SRD5A2 promoter methylation of 42 prostatic specimens and 12 metastatic biopsies and
found significant hypermethylation of SRD5A2 promoter region for CRPC compared with
benign prostatic specimens. Contrary to common belief that DNA methylation occurs during
tumor initiation and progression [18], we demonstrated that hypermethylation of SRD5A2 in
the whole promoter region (cytosine-phosphate-guanine [CpG]# -72 to +65) was correlated
with better OS and progression free survival (PFS) of CRPC patients, and hypermethylation of
promoter subset, CpG sites (CpG # -39 to -2), was best correlated with OS and PFS of CRPC
patients. Our study suggests that SRD5A2 methylation in promoter regions, specifically at
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CpG# -39 to -2, a condition that favors an estrogenic as opposed to an androgenic milieu in
the prostate, is significantly associated with better survival for CRPC patients treated with
ADT. Recognition of epigenetic modifications of SRD5A2, which affects the prostatic hor-




With the approval of institutional review board at Massachusetts General Hospital (MGH)
and Dana-Farber Cancer Institute, a total of 58 CRPC specimens and 36 benign prostatic spec-
imens were used for methylation testing. Written consent was obtained from the study partici-
pants for the two cohorts.The Local CRPC cohort patients were diagnosed as CRPC between
2004 and 2013. Forty two formalin-fixed paraffin-embedded (FFPE) prostatic specimens were
collected from patients who underwent transurethral resection of the prostate (TURP) at
MGH to relieve patients’ urinary outflow obstruction from locally advanced PCa. All patients
had received primary or secondary ADT. Pathology samples were reviewed by an expert geni-
tourinary pathologist (CLW). As controls, 12 frozen benign prostatic specimens were collected
from patients who underwent TURP for symptomatic benign prostatic hyperplasia (BPH) at
MGH. The metastatic cohort included 12 metastatic biopsies that were collected from CRPC
patients who were treated with abiraterone plus dutasteride (Clinical Trial NCT01393730). For
comparison with this cohort, 24 benign prostatic specimens were collected from patients who
underwent TURP for symptomatic BPH at MGH.
DNA methylation test: Targeted Next-Gen Bisulfite Sequencing (tNGBS)
technique
Test procedure is described in Supplementary Information.
Immunohistochemistry
IHC was completed as previously described [16, 17]. More detail is described in the Supple-
mentary Information.
TCGA prostate cancer data mining
The data of SRD5A2 promoter methylation and expression of SRD5A2 in normal prostatic
specimens and primary PCa specimens from The Cancer Genome Atlas (TCGA) database:
https://tcga-data.nci.nih.gov/tcga/ was extracted. The promoter methylation and expression of
SRD5A2 between normal and tumor tissues were compared via the UALCAN website: http://
ualcan.path.uab.edu [19]. The association between SRD5A2 promoter methylation and
SRD5A2 expression was analyzed via the MEXPRESS website: https://mexpress.be [20].
Statistical analysis
Continuous variables were reported as the means ± SD. The mean differences of average meth-
ylation ratios of SRD5A2 promoter between CRPC and benign prostatic tissues were compared
using the Student’s t-test. A heatmap was generated to compare the average methylation ratios
between the two groups and identify the specific promoter regions with the most significant
difference. R package “pheatmap” (version 1.0.12, https://cran.r-project.org/web/packages/
pheatmap; R software 3.6.0) was used to draw the heatmap of methylation sites in the two
cohorts, respectively. Those methylation sites were automatically clustered according to the
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“Euclidean” distance. With a cutoff value of the ratio of SRD5A2 promoter methylation, CRPC
patients were further sub-grouped as SRD5A2-hypermethylation group and SRD5A2-hypo-
methylation group. Cutoff values were determined by X-tail software (version 3.6.1; Yale Uni-
versity, New Haven, USA). OS and PFS data of the CRPC patients were retrieved and
calculated, then the ratio of SRD5A2 promoter methylation was correlated to the prognosis of
disease with survival curve and correlation analysis. Hazard ratios (HRs) of SRD5A2 promoter
methylation in predicting the OS and PFS of CRPC patients receiving ADT were calculated
using the Cox proportional hazards regression model and tested using the log-rank test. Multi-
variable analyses were performed, including GS, PSA, and ratio of SRD5A2 methylation as
covariates. A P value of< 0.05 was considered as statistical significance. All the statistical anal-
yses were conducted by R (version 3.5.2; The R Foundation, Vienna, Austria) and GraphPad
Prism (version 7.00; GraphPad Software, Inc., La Jolla, USA).
Results
Hypermethylation of the SRD5A2 promoter region for CRPC
Several independent studies have shown that expression of SRD5A1 is increased and SRD5A2
is decreased in the transition from hormone-naive PCa to CRPC [1, 13, 21, 22]. However, the
mechanism and clinical significance of changes associated with SRD5A2 in CRPC is poorly
understood. To explore whether epigenetic changes of SRD5A2 affects the therapeutic efficacy
of ADT, we tested and compared SRD5A2 promoter methylation ratios between CRPC and
benign prostatic tissues using the NGBS technique. We found that the methylation ratios of
main SRD5A2 promoter regions were higher for CRPC prostatic tissues compared with benign
prostatic tissues in the local CRPC cohort (Fig 1A). To identify methylation in the SRD5A2
specific promoter region, we performed unsupervised cluster analysis of the ratio of SRD5A2
promoter methylation on all CpG methylation sites. The CpG methylation sites were clustered
into three modules, CpG# -72 to -42; CpG#-40 to -35 / CpG# -31 to -19; CpG# -34 to -32 /
CpG# -18 to 65 (Fig 1C).
Validating our finding in Met CRPC tissues demonstrated a similar finding as the Local
CRPC cohort, i.e., higher methylation ratio of SRD5A2 for CRPC patients compared with that
in the benign control (Fig 1B). In addition, unsupervised cluster analysis generated two mod-
ules, CpG# -72 to -35; CpG# -34 to -32 / CpG# -30 to 65 (Fig 1D). After analysis of the Local
and Met CRPC cohorts, we identified CpG# -39 to 65 as the important region that is differen-
tially methylated between CRPC vs. benign prostatic samples.
We further verified our finding with Student’s t-test based quantitative analyses. The aver-
age methylation ratios of the whole SRD5A2 promoter region (CpG#-72 to 65) and specific
promoter region CpG#-39 to 65 of CRPC tissues were significantly higher than that of benign
prostatic tissues in the Local CRPC cohort (Fig 1E and 1I) and in the Met CRPC cohort (Fig
1F and 1J). However, there was no significant difference in the average methylation ratios of
region CpG#-72 to -40 between CRPC and benign control groups (Fig 1G and 1H).
Higher ratio of SRD5A2 promoter methylation was correlated with better
prognosis of CRPC patients receiving ADT
We next addressed whether the SRD5A2 promoter methylation is correlated to the clinical effi-
ciency of ADT for CRPC patients. CRPC patients were sub-grouped as the SRD5A2 hyper-
methylation group and the SRD5A2 hypomethylation group using the best cutoff value of
methylation ratios. In the Local CRPC cohort, data of the whole promoter region of SRD5A2
PLOS ONE SRD5A2 methylation predicts a better outcome for CRPC
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Fig 1. Hypermethylation of the SRD5A2 promoter region in CRPC. (A) The ratio of SRD5A2 promoter methylation
on individual CpG sites in the promoter region in CRPC and benign prostatic tissues in the Local CRPC cohort. (B)
The ratio of SRD5A2 DNA promoter methylation on individual CpG sites in CRPC and benign prostatic tissues in the
Met CRPC cohort. (C) Unsupervised cluster analysis of the ratio of SRD5A2 promoter methylation on all CpG
methylation sites in the Local CRPC cohort. The CpG methylation sites were clustered into 3 modules, CpG# -72 to
-42; CpG# -40 to -35 and -31 to -19; CpG# -34 to -32 and -18 to 65. (D) Unsupervised cluster analysis of the ratio of
SRD5A2 promoter methylation on all the CpG methylation sites in the Met CRPC cohort. The methylation sites were
clustered into 2 modules, CpG# -72 to -35, -31; CpG# -34 to -32 and -30 to 65. (E) The average methylation level of all
PLOS ONE SRD5A2 methylation predicts a better outcome for CRPC
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(CpG#-72 to 65) was generated as a Heatmap (Fig 2A), which revealed the different levels of
methylation between the two groups.
Next, we retrieved OS and PFS data of the CRPC patients and correlated the ratio of
SRD5A2 promoter methylation to the prognosis of disease with a survival curve and correla-
tion analysis. We found that a higher methylation ratio was significantly correlated with better
OS of CRPC patients receiving ADT (S1 and S2 Tables, 12.0 ± 6.3 vs 8.0 ± 4.8 years, P = 0.013;
Fig 2B and 2C) and better PFS (S1 and S2 Tables, 8.4 ± 5.6 vs 5.3 ± 4.2 years, P = 0.045; Fig 2D
and 2E). Similarly, in the Met CRPC cohort, the Heatmap demonstrated the difference of
methylation in whole promoter region of SRD5A2 (CpG#-72 to 65) between the two groups
(S2A Fig), and a higher methylation ratio was significantly associated with better OS
(18.2 ± 5.2 vs 7.9 ± 4.3 years, P = 0.01, S2B and S2C Fig) and better PFS (10.0 ± 4.8 vs 5.0 ± 1.2
months, P = 0.002, S2D and S2E Fig). Together, our data suggest that SRD5A2 whole promoter
region methylation both in prostatic tissue and metastatic biopsies predicts a better outcome
of ADT treatment for CRPC patients.
Higher ratio of SRD5A2 methylation in specific promoter regions was
correlated with better prognosis of CRPC patients receiving ADT
Next, we sought to investigate if the methylation in more specific SRD5A2 promoter regions
better predict the outcome of ADT treatment. We first focused our study on a specific pro-
moter region CpG# -39 to 65 (Fig 1I and 1J). As expected, in the local CRPC cohort, a higher
methylation ratio was significantly associated with better OS (P = 0.038, Fig 3A and 3B) and
better PFS (P = 0.019, Fig 3C and 3D). Similarly, in the Met CRPC cohort, higher methylation
was also significantly associated with better OS (P = 0.056, Fig 3E and 3F) and better PFS
(P = 0.02, Fig 3G and 3H).
Furthermore, we expected to find the best promoter regions, which might be more predic-
tive of the outcome of ADT treatment. Among the series of promoter regions, the region
located at CpG# -39 to -2 had the most statistically significant value in the Local CRPC cohort
(S1 Table). Higher methylation of this specific region (nucleotides -434 to -4 [CpG# -39 to
CpG# -2]) was associated with better OS (11.3 ± 5.8 vs 6.4 ± 4.4 years, P = 0.001) and PFS
(8.4 ± 5.4 vs 4.5 ± 3.9 years, P = 0.003) with a cutoff value of 37.9% (S1 Table and Fig 4). Simi-
larly, in the Met CRPC cohort, higher methylation of this specific region was also significantly
associated with OS (8.4 ± 4.3 vs 14.6 ± 8.2 years, P = 0.04) and PFS (5.0 ± 1.2 vs 10.0 ± 4.8
years, P = 0.002) with a cutoff value of 47% (S2 Table and S3 Fig). Our data suggest that hyper-
methylation in specific region, nucleotides -434 to -4 (CpG# -39 to CpG# -2) might be a good
marker to predict the ADT sensitivity for CRPC patients.
In addition, multivariable analysis demonstrated that SRD5A2 methylation both in the
whole promoter region and specific region (CpG# -39 to -2) was associated with OS indepen-
dent from GS and PSA (S3 Table, whole promoter region: P = 0.03; CpG# -39 to -2: P = 0.02).
tested CpG methylation sites in CRPC and benign prostatic tissues in the Local CRPC cohort. (F) The average
methylation level of all tested CpG methylation sites in CRPC and benign prostatic tissues in the Met CRPC cohort.
(G) The average methylation level of module 1: CpG# -72 to -40 in CRPC and benign prostatic tissues in the Local
CRPC cohort. (H) The average methylation level of module 1: CpG# -72 to -40 in CRPC and benign prostatic tissues in
the Met CRPC cohort. (I) The average methylation level of module 2: CpG# -39 to 65 in CRPC and benign prostatic
tissues in the Local CRPC cohort. (J) The average methylation level of module 2: CpG# -39 to 65 in CRPC and benign
prostatic tissues in the Met CRPC cohort.
https://doi.org/10.1371/journal.pone.0229754.g001
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SRD5A2 promoter methylation was negatively associated with SRD5A2
expression
Finally, we sought to investigate if SRD5A2 promoter methylation is associated with SRD5A2
expression. IHC data demonstrated that the protein expression of SRD5A2 was negatively cor-
related with its methylation ratio both in the whole promoter region (CpG# -72 to CpG# 65)
(R = 0.235, P = 0.0011) and specific region (CpG# -39 to CpG# -2) (R = 0.287, P = 0.0003) (Fig
5A–5C).
Then, we validated our finding using the publicly available TCGA dataset. The data of
SRD5A2 promoter methylation from 502 primary PCa tissues and 50 normal control prostatic
Fig 2. Hypermethylation of SRD5A2 in the whole promoter region (CpG # -72 to 65) was correlated with OS and
PFS of CRPC patients in the Local CRPC cohort. Patients were divided into a hypermethylation group and a
hypomethylation group with a cutoff value of 46.5%, based on the average methylation level of all methylation sites. (A)
Unsupervised cluster analysis of the ratio of SRD5A2 promoter methylation on all CpG methylation sites. (B) The
difference of OS between the hypermethylation group and hypomethylation group. (C) The correlation between
methylation level and OS. (D & E) Patients were divided into a hypermethylation group and a hypomethylation group
with a cutoff value of 42%, based on the average methylation level of all methylation sites. (D) The difference of PFS
between the two groups. (E) The correlation between methylation level and PFS.
https://doi.org/10.1371/journal.pone.0229754.g002
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Fig 3. SRD5A2 hypermethylation of specific CpG sites (CpG # -39 to 65) in the promoter region was correlated
with OS and PFS of CRPC patients. Survival analysis was done based on clustering analysis of methylation site
modules (CpG#-39 to 65 average methylation level). (A to D) In the Local CRPC cohort, patients were divided into a
hypermethylation group and a hypomethylation group with a cutoff value of 23.3%, based on the average methylation
level of specific CpG sites (CpG# -39 to 65). (A) The difference of OS between the two groups. (B) The correlation
between SRD5A2 promoter methylation level and OS. (C) The difference of PFS between the two groups. (D) The
correlation between methylation level and PFS. (E to H) In the Met CRPC cohort, patients were divided into a
hypermethylation group and a hypomethylation group with a cutoff value of 28.0%, based on the average methylation
level of specific CpG sites (CpG# -39 to 65). (E) The difference of OS between the two groups. (F) The correlation
between methylation level and OS. (G) The difference of PFS between the two groups. (H) The correlation between
methylation level and PFS.
https://doi.org/10.1371/journal.pone.0229754.g003
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tissues were extracted from TCGA. We found that the promoter regions of SRD5A2 of PCa
specimen were significantly hypermethylated compared with normal prostatic tissues
(P< 0.0001, Fig 5D). To compare the expression of SRD5A2, 497 primary PCa tissues and 52
normal prostatic tissues were analyzed, and we found that the expression of SRD5A2 in pri-
mary PCa tissues was significantly lower than the normal prostatic tissues (P < 0.0001, Fig
5E). Furthermore, we found that the methylation levels of most sites of the SRD5A2 promoter
were negatively correlated with expression of SRD5A2. Three of SRD5A2 promoter sites had
Fig 4. SRD5A2 hypermethylation of specific CpG sites (CpG # -39 to -2) in the promoter region was correlated
with OS and PFS of CRPC patients in the Local CRPC cohort. Patients were divided into a hypermethylation group
and a hypomethylation group with a cutoff value of 37.9%, based on the average methylation level of specific CpG sites
(CpG# -39 to -2). (A) Unsupervised cluster analysis of the ratio of SRD5A2 promoter methylation on CpG methylation
sites (CpG # -39 to -2). (B) The difference of OS between the hypermethylation group and hypomethylation group. (C)
The correlation between methylation level and OS. (D) The difference of PFS between the two groups. (E) The
correlation between SRD5A2 methylation and PFS.
https://doi.org/10.1371/journal.pone.0229754.g004
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the highest correlation with SRD5A2 expression, which were cg26638505 (CpG# -25, R =
-0.489), cg06492144 (CpG# -35, R = -0.393) and cg08894761 (CpG# -25, R = -0.383), sites that
overlap with CpG# -39 to CpG# -2 (Fig 5F). The data here further supports our finding that
hypermethylation in specific region CpG# -39 to -2 might be a good marker to predict the
ADT sensitivity for CRPC patients.
Fig 5. Protein expression of SRD5A2 was negatively correlated with SRD5A2 promoter methylation. (A to C) IHC
with anti-SRD5A2 antibody. (A) Representative pictures of IHC. (B) The immunoreactive score was correlated with
SRD5A2 promoter methylation on CpG# -72 to 65. (C) The immunoreactive score was correlated with SRD5A2
promoter methylation on CpG# -39 to -2. (D to F) TCGA data analysis. (D) SRD5A2 promoter methylation in primary
PCa. (E) SRD5A2 expression in primary PCa. (F) The association between SRD5A2 promoter methylation and
SRD5A2 expression. Blue rows represented the methylation levels of SRD5A2 promoter region, yellow rows
represented SRD5A2 expression, and each column represented one sample.
https://doi.org/10.1371/journal.pone.0229754.g005
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Discussion
SRD5A2 is the predominant isoform of 5-α reductase expressed in the prostate, whereas
SRD5A1 represents less than 10% of total 5α-reductase levels in normal prostate cells [23]. In
PCa cells, the expression of SRD5A2 decreases, but the expression of SRD5A1 increases [21–
24]. These two enzymes have been associated with PCa initiation and PCa progression. For
instance, studies on polymorphisms in SRD5A1 and SRD5A2 have suggested its association
with PCa risk and PCa recurrence [25–27]. However, SRD5A2 rs9282858, the common nonsy-
nonymous single nucleotide polymorphism was found not significantly associate with PCa
risk [25]. Therefore, further studies are warranted to identify how the epigenetic change of
these enzymes effects on PCa. To our knowledge, ours is the first study to analyze the associa-
tion of epigenetic change of SRD5A2 with response to ADT for CRPC patients. In contradis-
tinction to widely held assumptions that DNA methylation is correlated with cancer
progression, our findings show that hypermethylation in the SRD5A2 promoter region, specif-
ically CpG# -39 to -2, predicted better OS and PFS for patients with CRPC. The study suggests
that quantitative SRD5A2 methylation analysis in a pre-treatment biopsy could allow identifi-
cation of patients most likely to benefit and facilitate tailoring of ADT therapy. For example,
PCa patients with SRD5A2 methylation may benefit less from intensified AR-directed therapy,
or from early addition of docetaxel in castration-sensitive metastatic disease [28, 29]. Alterna-
tively, patients with SRD5A2 methylation may respond differently to androgen signaling
inhibitors or targeted therapies toward the estrogen receptor pathway may prove beneficial in
this subset of patients.
Tumor cells can be activated by epigenetic alterations, and further use epigenetic processes
to escape from chemotherapy and host immune surveillance. Therefore, targeting the epigen-
ome, including DNA methylation and histone modifications has been a growing emphasis of
recent drug discovery [18]. In our study, data from two cohorts demonstrated that there is
hypermethylation of SRD5A2 promoter in CRPC compared with benign prostatic tissues (Fig
1). This result was further confirmed by analyzing TCGA data (Fig 5). Most interestingly, we
found that SRD5A2 methylation in promoter regions, specifically at CpG# -39 to CpG# -2, is
significantly associated with better survival for CRPC patients treated with ADT. Being consis-
tent with the study for high-risk gliomas which showed that MGMT promoter methylation
predicts better survival outcomes [30], our finding not only provides evidence that alteration
of the epigenome is an important step in cancer progression, but also opens new windows of
opportunities in personalized medicine for CRPC patients.
There are several methods to test for DNA methylation or a CpG island in the promoter
region of a single gene. The most widely used methods include pyrosequencing, methylation-
specific polymerase chain reaction (PCR), and direct Sanger sequencing. In this study we used
the tNGBS technique to test the methylation of the SRD5A2 promoter region, which allowed us
to analyze massive quantities of CpG sites for methylation [31, 32]. While we analyzed methyla-
tion of single CpG site in the SRD5A2 promoter region, our future study will identify whether
single CpG site(s) methylation within a CpG island shore of the SRD5A2 gene contribute(s) to
alteration in SRD5A2 expression and subsequent acquisition of treatment resistance.
Here, we present evidence that SRD5A2 promoter methylation could be used as a prognos-
tic marker for CRPC patients treated with ADT. An explanation could be that SRD5A2 pro-
moter hypermethylation causes the absence of SRD5A2 expression, and an androgenic to
estrogenic switch in prostate tissue. This hypothesis is supported by our recent studies and oth-
ers [17, 33–35]. In BPH tissues, we showed that the level of estradiol is dramatically elevated in
prostatic samples with methylation of the SRD5A2 promoter, a condition that favors an estro-
genic, as opposed to an androgenic, milieu in the prostate. The phosphorylation of estrogen
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receptor-α (ERα) in prostatic stroma is upregulated when SRD5A2 expression is absent [17].
During PCa initiation, not only androgens but also estrogens are required for malignant trans-
formation [34, 35], suggesting that there is a role for AR/ERα cooperation in androgen tar-
geted therapy resistance. Therefore, combination of treatments targeting both AR and ERα
pathways may improve therapies for management of CRPC [34, 36]. Together, we postulate
that SRD5A2 methylation in promoter regions, a condition that favors an estrogenic, as
opposed to an androgenic milieu in the prostate, is significantly associated with better survival
for CRPC patients treated with ADT. Further studies are warranted to examine whether hor-
monal interventions play a role in CRPC disease progression and treatment efficiency.
Supporting information
S1 Fig. SRD5A2 DNA methylation profiling.
(PPTX)
S2 Fig. Hypermethylation of SRD5A2 in the whole promoter region (CpG # -72 to 65) was
correlated with overall survival (OS) and progression free survival (PFS) of castration-
resistant prostate cancer (CRPC) patients in the metastatic (Met) CRPC cohort. Patients
were divided into a hypermethylation group and a hypomethylation group with a cutoff value
of 40.0%, based on the average methylation level of all methylation sites. (A) Unsupervised
cluster analysis of the ratio of SRD5A2 promoter methylation on all CpG methylation sites. (B)
The difference of OS between the hypermethylation group and the hypomethylation group.
(C) The correlation between methylation level and OS. (D & E) Patients were divided into a
hypermethylation group and a hypomethylation group with a cutoff value of 32.5%, based on
the average methylation level of all methylation sites. (D) The difference of PFS between hyper-
methylation group and hypomethylation group. (E) The correlation between SRD5A2 pro-
moter methylation level and PFS.
(TIF)
S3 Fig. In the Met CRPC cohort, patients were divided into a hypermethylation group and
a hypomethylation group with a cutoff value of 47%, based on the average methylation
level of specific CpG sites (CpG# -39 to -2). (A) Unsupervised cluster analysis of the ratio of
SRD5A2 promoter methylation. (B) The difference of OS between the two groups. (C) The cor-
relation between methylation level and OS. (D & E) Patients were divided into a hypermethy-
lation group and a hypomethylation group with a cutoff value of 37.8%, based on the average
methylation level of specific CpG sites (CpG# -39 to -2). (D) The difference of PFS between
the two groups. (E) The correlation between methylation level and PFS.
(TIF)




S1 Table. Cutoff values of SRD5A2 promoter methylation in Local CRPC cohort.
(DOCX)
S2 Table. Cutoff values of SRD5A2 promoter methylation in Met CRPC cohort.
(DOCX)
S3 Table. Multivariable regression analyses.
(DOCX)
PLOS ONE SRD5A2 methylation predicts a better outcome for CRPC
PLOS ONE | https://doi.org/10.1371/journal.pone.0229754 March 5, 2020 12 / 15
Author Contributions
Conceptualization: Zongwei Wang, Aria F. Olumi.
Data curation: Zongwei Wang, Tuo Deng, Xingbo Long, Shulin Wu.
Formal analysis: Zongwei Wang, Tuo Deng, Xingbo Long, Shulin Wu.
Funding acquisition: Aria F. Olumi.
Investigation: Tuo Deng, Xueming Lin, Hongbo Wang.
Methodology: Xueming Lin, Hongbo Wang, Rongbin Ge.
Project administration: Aria F. Olumi.
Resources: Zhenwei Zhang, Chin-Lee Wu, Mary-Ellen Taplin.
Writing – original draft: Zongwei Wang.
Writing – review & editing: Aria F. Olumi.
References
1. Chang KH, Li R, Papari-Zareei M, Watumull L, Zhao YD, Auchus RJ, et al. Dihydrotestosterone synthe-
sis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2011;
108(33):13728–33. Epub 2011/07/29. https://doi.org/10.1073/pnas.1107898108 PMID: 21795608;
PubMed Central PMCID: PMC3158152.
2. Society AC. Cancer Facts & Figures 2019 2019. Available from: https://www.cancer.org/research/
cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2019.html
3. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in meta-
static prostate cancer before chemotherapy. N Engl J Med. 2014; 371(5):424–33. https://doi.org/10.
1056/NEJMoa1405095 PMID: 24881730; PubMed Central PMCID: PMC4418931.
4. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival
in metastatic prostate cancer. N Engl J Med. 2011; 364(21):1995–2005. https://doi.org/10.1056/
NEJMoa1014618 PMID: 21612468; PubMed Central PMCID: PMC3471149.
5. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic
prostate cancer without previous chemotherapy. N Engl J Med. 2013; 368(2):138–48. Epub 2012/12/
12. https://doi.org/10.1056/NEJMoa1209096 PMID: 23228172; PubMed Central PMCID:
PMC3683570.
6. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzaluta-
mide in prostate cancer after chemotherapy. N Engl J Med. 2012; 367(13):1187–97. Epub 2012/08/17.
https://doi.org/10.1056/NEJMoa1207506 PMID: 22894553.
7. Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Darolutamide in Nonmetastatic,
Castration-Resistant Prostate Cancer. N Engl J Med. 2019; 380(13):1235–46. Epub 2019/02/15.
https://doi.org/10.1056/NEJMoa1815671 PMID: 30763142.
8. Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide Treatment
and Metastasis-free Survival in Prostate Cancer. N Engl J Med. 2018; 378(15):1408–18. Epub 2018/02/
09. https://doi.org/10.1056/NEJMoa1715546 PMID: 29420164.
9. Russo JW, Gao C, Bhasin SS, Voznesensky OS, Calagua C, Arai S, et al. Downregulation of Dipeptidyl
Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer. Cancer Res. 2018; 78
(22):6354–62. Epub 2018/09/23. https://doi.org/10.1158/0008-5472.CAN-18-0687 PMID: 30242112;
PubMed Central PMCID: PMC6239953.
10. Li Z, Alyamani M, Li J, Rogacki K, Abazeed M, Upadhyay SK, et al. Redirecting abiraterone metabolism
to fine-tune prostate cancer anti-androgen therapy. Nature. 2016; 533(7604):547–51. https://doi.org/10.
1038/nature17954 PMID: 27225130.
11. Audet-Walsh E, Yee T, Tam IS, Giguere V. Inverse Regulation of DHT Synthesis Enzymes 5alpha-
Reductase Types 1 and 2 by the Androgen Receptor in Prostate Cancer. Endocrinology. 2017; 158
(4):1015–21. Epub 2017/03/23. https://doi.org/10.1210/en.2016-1926 PMID: 28324044.
12. Mitsiades N, Sung CC, Schultz N, Danila DC, He B, Eedunuri VK, et al. Distinct patterns of dysregulated
expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer
tumors. Cancer Res. 2012; 72(23):6142–52. Epub 2012/09/14. https://doi.org/10.1158/0008-5472.
CAN-12-1335 PMID: 22971343; PubMed Central PMCID: PMC3685485.
PLOS ONE SRD5A2 methylation predicts a better outcome for CRPC
PLOS ONE | https://doi.org/10.1371/journal.pone.0229754 March 5, 2020 13 / 15
13. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, et al. Maintenance of
intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor
growth. Cancer Res. 2008; 68(11):4447–54. Epub 2008/06/04. https://doi.org/10.1158/0008-5472.
CAN-08-0249 PMID: 18519708; PubMed Central PMCID: PMC2536685.
14. Shiota M, Fujimoto N, Yokomizo A, Takeuchi A, Itsumi M, Inokuchi J, et al. SRD5A gene polymorphism
in Japanese men predicts prognosis of metastatic prostate cancer with androgen-deprivation therapy.
Eur J Cancer. 2015; 51(14):1962–9. Epub 2015/07/15. https://doi.org/10.1016/j.ejca.2015.06.122
PMID: 26169017.
15. Bechis SK, Otsetov AG, Ge R, Wang Z, Vangel MG, Wu CL, et al. Age and Obesity Promote Methyla-
tion and Suppression of 5-Alpha Reductase 2- Implications for Personalized Therapy in Benign Pros-
tatic Hyperplasia. The Journal of urology. 2015. https://doi.org/10.1016/j.juro.2015.04.079 PMID:
25916673.
16. Ge R, Wang Z, Bechis SK, Otsetov AG, Hua S, Wu S, et al. DNA methyl transferase 1 reduces expres-
sion of SRD5A2 in the aging adult prostate. The American journal of pathology. 2015; 185(3):870–82.
https://doi.org/10.1016/j.ajpath.2014.11.020 PMID: 25700986; PubMed Central PMCID: PMC4348471.
17. Wang Z, Hu L, Salari K, Bechis SK, Ge R, Wu S, et al. Androgenic to oestrogenic switch in the human
adult prostate gland is regulated by epigenetic silencing of steroid 5alpha-reductase 2. The Journal of
pathology. 2017; 243(4):457–67. https://doi.org/10.1002/path.4985 PMID: 28940538.
18. Jones PA, Issa JP, Baylin S. Targeting the cancer epigenome for therapy. Nat Rev Genet. 2016; 17
(10):630–41. Epub 2016/09/16. https://doi.org/10.1038/nrg.2016.93 PMID: 27629931.
19. Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi
B, et al. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses.
Neoplasia. 2017; 19(8):649–58. Epub 2017/07/22. https://doi.org/10.1016/j.neo.2017.05.002 PMID:
28732212; PubMed Central PMCID: PMC5516091.
20. Koch A, De Meyer T, Jeschke J, Van Criekinge W. MEXPRESS: visualizing expression, DNA methyla-
tion and clinical TCGA data. BMC Genomics. 2015; 16:636. Epub 2015/08/27. https://doi.org/10.1186/
s12864-015-1847-z PMID: 26306699; PubMed Central PMCID: PMC4549898.
21. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, et al. Increased expression of
genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer
Res. 2006; 66(5):2815–25. Epub 2006/03/03. https://doi.org/10.1158/0008-5472.CAN-05-4000 PMID:
16510604.
22. Titus MA, Gregory CW, Ford OH 3rd, Schell MJ, Maygarden SJ, Mohler JL. Steroid 5alpha-reductase
isozymes I and II in recurrent prostate cancer. Clin Cancer Res. 2005; 11(12):4365–71. Epub 2005/06/
17. https://doi.org/10.1158/1078-0432.CCR-04-0738 PMID: 15958619.
23. Thomas LN, Lazier CB, Gupta R, Norman RW, Troyer DA, O’Brien SP, et al. Differential alterations in
5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer.
Prostate. 2005; 63(3):231–9. Epub 2004/11/13. https://doi.org/10.1002/pros.20188 PMID: 15538746.
24. Elo JP, Akinola LA, Poutanen M, Vihko P, Kyllonen AP, Lukkarinen O, et al. Characterization of 17beta-
hydroxysteroid dehydrogenase isoenzyme expression in benign and malignant human prostate. Int J
Cancer. 1996; 66(1):37–41. Epub 1996/03/28. https://doi.org/10.1002/(SICI)1097-0215(19960328)
66:1<37::AID-IJC7>3.0.CO;2-# PMID: 8608963.
25. Price DK, Chau CH, Till C, Goodman PJ, Leach RJ, Johnson-Pais TL, et al. Association of androgen
metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from
the Prostate Cancer Prevention Trial. Cancer. 2016; 122(15):2332–40. Epub 2016/05/11. https://doi.
org/10.1002/cncr.30071 PMID: 27164191; PubMed Central PMCID: PMC4956504.
26. Audet-Walsh E, Bellemare J, Nadeau G, Lacombe L, Fradet Y, Fradet V, et al. SRD5A polymorphisms
and biochemical failure after radical prostatectomy. European urology. 2011; 60(6):1226–34. Epub
2011/07/01. https://doi.org/10.1016/j.eururo.2011.06.020 PMID: 21715084.
27. Sissung TM, Price DK, Del Re M, Ley AM, Giovannetti E, Figg WD, et al. Genetic variation: effect on
prostate cancer. Biochim Biophys Acta. 2014; 1846(2):446–56. Epub 2014/09/10. https://doi.org/10.
1016/j.bbcan.2014.08.007 PMID: 25199985; PubMed Central PMCID: PMC4260983.
28. Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with Standard
First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med. 2019. Epub 2019/06/04. https://doi.
org/10.1056/NEJMoa1903835 PMID: 31157964.
29. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal Therapy
in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015; 373(8):737–46. Epub 2015/08/
06. https://doi.org/10.1056/NEJMoa1503747 PMID: 26244877; PubMed Central PMCID:
PMC4562797.
30. Bell EH, Zhang P, Fisher BJ, Macdonald DR, McElroy JP, Lesser GJ, et al. Association of MGMT Pro-
moter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With
PLOS ONE SRD5A2 methylation predicts a better outcome for CRPC
PLOS ONE | https://doi.org/10.1371/journal.pone.0229754 March 5, 2020 14 / 15
Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial. JAMA
Oncol. 2018; 4(10):1405–9. Epub 2018/06/30. https://doi.org/10.1001/jamaoncol.2018.1977 PMID:
29955793; PubMed Central PMCID: PMC6117103.
31. Barros-Silva D, Marques CJ, Henrique R, Jeronimo C. Profiling DNA Methylation Based on Next-Gener-
ation Sequencing Approaches: New Insights and Clinical Applications. Genes (Basel). 2018; 9(9). Epub
2018/08/26. https://doi.org/10.3390/genes9090429 PMID: 30142958; PubMed Central PMCID:
PMC6162482.
32. Laird PW. Principles and challenges of genomewide DNA methylation analysis. Nat Rev Genet. 2010;
11(3):191–203. Epub 2010/02/04. https://doi.org/10.1038/nrg2732 PMID: 20125086.
33. Andriole GL, Guess HA, Epstein JI, Wise H, Kadmon D, Crawford ED, et al. Treatment with finasteride
preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a ran-
domized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Effi-
cacy and Safety Study. Urology. 1998; 52(2):195–201; discussion -2. https://doi.org/10.1016/s0090-
4295(98)00184-8 PMID: 9697781.
34. Fujimura T, Takayama K, Takahashi S, Inoue S. Estrogen and Androgen Blockade for Advanced Pros-
tate Cancer in the Era of Precision Medicine. Cancers (Basel). 2018; 10(2). Epub 2018/01/24. https://
doi.org/10.3390/cancers10020029 PMID: 29360794; PubMed Central PMCID: PMC5836061.
35. Ricke WA, Ishii K, Ricke EA, Simko J, Wang Y, Hayward SW, et al. Steroid hormones stimulate human
prostate cancer progression and metastasis. International journal of cancer. 2006; 118(9):2123–31.
https://doi.org/10.1002/ijc.21614 PMID: 16331600.
36. Sehgal PD, Bauman TM, Nicholson TM, Vellky JE, Ricke EA, Tang W, et al. Tissue-specific quantifica-
tion and localization of androgen and estrogen receptors in prostate cancer. Hum Pathol. 2019; 89:99–
108. Epub 2019/05/06. https://doi.org/10.1016/j.humpath.2019.04.009 PMID: 31054895; PubMed Cen-
tral PMCID: PMC6642018.
37. McKay RR, Werner L, Mostaghel EA, Lis R, Voznesensky O, Zhang Z, et al. A Phase II Trial of Abirater-
one Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer. Clin
Cancer Res. 2017; 23(4):935–45. Epub 2016/09/30. https://doi.org/10.1158/1078-0432.CCR-16-0987
PMID: 27683182; PubMed Central PMCID: PMC5315609.
PLOS ONE SRD5A2 methylation predicts a better outcome for CRPC
PLOS ONE | https://doi.org/10.1371/journal.pone.0229754 March 5, 2020 15 / 15
